Effects of Pregabalin on Heart Rate Variability in Patients With Painful Diabetic Neuropathy
Authors:
- Wei JiangWJWei Jiang
- Shelby LaddSLShelby Ladd
- Carolyn MartsbergerCMCarolyn Martsberger
- Mark FeinglosMFMark Feinglos
- Susan E. SprattSSSusan E. Spratt
- Maragatha KuchibhatlaMKMaragatha Kuchibhatla
- Jennifer GreenJGJennifer Green
- Ranga KrishnanRKRanga Krishnan
- 1 April 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 31 (2) , 207-213
Abstract
Many studies have demonstrated that low heart rate variability (HRV) is a risk for high mortality and morbidity in patients with cardiovascular diseases. The primary purpose of the study was to evaluate whether pregabalin improves HRV in patients with diabetes and painful peripheral neuropathy. Resting heart rates were collected by using the LifeShirt System, developed by VivoMetrics (Ventura, Calif), at baseline and at the end of a 4-week intervention of pregabalin or placebo in patients with painful diabetic peripheral neuropathy. Heart rate variability analysis was performed on the collected R-R intervals using the Vivo- VMLA-036-00 3 Logic of the LifeShirt system. Of the 40 patients enrolled in the study, 70% completed the end of 4-week assessments (n = 15 in pregabalin and n = 14 in placebo). Compared with placebo, pregabalin treatment resulted in significant improvement in HRV measured by frequency domain analysis, that is, a reduction in low frequency-high frequency ratio (-1.30 ± 2.89 vs 0.37 ± 0.33, P = 0.03) and power of normalized low frequency (-0.049 ± 0.092 vs 0.0066 ± 0.023, P = 0.02), as well as an increase in power of normalized high frequency (0.039 ± 0.094 vs -0.038 ± 0.066, P = 0.02). Furthermore, pregabalin resulted in greater reduction of pain and symptoms of anxiety and greater improvement of quality of life. The improvement of HRV measures were not correlated with change of those measures. In conclusion, 4-week pregabalin treatment improved HRV in patients with painful diabetic peripheral neuropathy. NCT00573261 (clinicaltrials.gov).Keywords
This publication has 29 references indexed in Scilit:
- Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarctionJACC, 2001
- Prognostic Significance of Heart Rate Variability in Post–Myocardial Infarction Patients in the Fibrinolytic EraCirculation, 1996
- Heart Rate VariabilityCirculation, 1996
- The ability of several short-term measures of RR variability to predict mortality after myocardial infarction.Circulation, 1993
- Frequency domain measures of heart period variability to assess risk late after myocardial infarctionJACC, 1993
- Time course of recovery of heart period variability after myocardial infarctionJACC, 1991
- Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogramJACC, 1991
- Decreased heart rate variability and its association with increased mortality after acute myocardial infarctionThe American Journal of Cardiology, 1987
- Power spectral analysis of heart rate and arterial pressure variabilities as a marker of sympatho-vagal interaction in man and conscious dog.Circulation Research, 1986
- Neural Activity and Ventricular FibrillationNew England Journal of Medicine, 1976